<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>http://api.elsevier.com/content/abstract/scopus_id/84912062545</prism:url><dc:identifier>SCOPUS_ID:84912062545</dc:identifier><eid>2-s2.0-84912062545</eid><prism:doi>10.1038/nrd4477</prism:doi><dc:title>Managing diabetes with nanomedicine: challenges and opportunities</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><citedby-count>0</citedby-count><prism:publicationName>Nature Reviews Drug Discovery</prism:publicationName><dc:publisher>
Nature Publishing Group

Houndmills
Basingstoke, Hampshire
RG21 6XS

</dc:publisher><source-id>20425</source-id><prism:issn>14741784</prism:issn><prism:coverDate>2014-11-28</prism:coverDate><dc:creator><author auid="8511017600" seq="1"><ce:initials>O.</ce:initials><ce:indexed-name>Veiseh O.</ce:indexed-name><ce:surname>Veiseh</ce:surname><ce:given-name>Omid</ce:given-name><preferred-name>
<ce:initials>O.</ce:initials>
<ce:indexed-name>Veiseh O.</ce:indexed-name>
<ce:surname>Veiseh</ce:surname>
<ce:given-name>Omid</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/8511017600</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60030521" id="60030521"/></author></dc:creator><dc:description><abstract original="y" xml:lang="eng">
<publishercopyright>Â© 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</publishercopyright>
<ce:para>Nanotechnology-based approaches hold substantial potential for improving the care of patients with diabetes. Nanoparticles are being developed as imaging contrast agents to assist in the early diagnosis of type 1 diabetes. Glucose nanosensors are being incorporated in implantable devices that enable more accurate and patient-friendly real-time tracking of blood glucose levels, and are also providing the basis for glucose-responsive nanoparticles that better mimic the body's physiological needs for insulin. Finally, nanotechnology is being used in non-invasive approaches to insulin delivery and to engineer more effective vaccine, cell and gene therapies for type 1 diabetes. Here, we analyse the current state of these approaches and discuss key issues for their translation to clinical practice.</ce:para>
</abstract></dc:description><link href="http://api.elsevier.com/content/abstract/scopus_id/84912062545" rel="self"/><link href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84912062545&amp;origin=inward" rel="scopus"/><link href="http://api.elsevier.com/content/search/scopus?query=refeid%282-s2.0-84912062545%29" rel="cited-by"/></coredata><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60030521" id="60030521"><affilname>Children's Hospital Boston</affilname></affiliation><authors><author auid="8511017600" seq="1"><ce:initials>O.</ce:initials><ce:indexed-name>Veiseh O.</ce:indexed-name><ce:surname>Veiseh</ce:surname><ce:given-name>Omid</ce:given-name><preferred-name>
<ce:initials>O.</ce:initials>
<ce:indexed-name>Veiseh O.</ce:indexed-name>
<ce:surname>Veiseh</ce:surname>
<ce:given-name>Omid</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/8511017600</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60030521" id="60030521"/></author><author auid="56428374900" seq="2"><ce:initials>B.C.</ce:initials><ce:indexed-name>Tang B.C.</ce:indexed-name><ce:surname>Tang</ce:surname><ce:given-name>Benjamin C.</ce:given-name><preferred-name>
<ce:initials>B.C.</ce:initials>
<ce:indexed-name>Tang B.</ce:indexed-name>
<ce:surname>Tang</ce:surname>
<ce:given-name>Benjamin C.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/56428374900</author-url></author><author auid="35609935600" seq="3"><ce:initials>K.A.</ce:initials><ce:indexed-name>Whitehead K.A.</ce:indexed-name><ce:surname>Whitehead</ce:surname><ce:given-name>Kathryn A.</ce:given-name><preferred-name>
<ce:initials>K.A.</ce:initials>
<ce:indexed-name>Whitehead K.</ce:indexed-name>
<ce:surname>Whitehead</ce:surname>
<ce:given-name>Kathryn A.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/35609935600</author-url></author><author auid="55561679100" seq="4"><ce:initials>D.G.</ce:initials><ce:indexed-name>Anderson D.G.</ce:indexed-name><ce:surname>Anderson</ce:surname><ce:given-name>Daniel G.</ce:given-name><preferred-name>
<ce:initials>D.G.</ce:initials>
<ce:indexed-name>Anderson D.</ce:indexed-name>
<ce:surname>Anderson</ce:surname>
<ce:given-name>Daniel G.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/55561679100</author-url></author><author auid="7402409226" seq="5"><ce:initials>R.</ce:initials><ce:indexed-name>Langer R.</ce:indexed-name><ce:surname>Langer</ce:surname><ce:given-name>Robert</ce:given-name><preferred-name>
<ce:initials>R.</ce:initials>
<ce:indexed-name>Langer R.</ce:indexed-name>
<ce:surname>Langer</ce:surname>
<ce:given-name>Robert</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7402409226</author-url></author></authors></abstracts-retrieval-response>
